Wherever possible, we aim to bring researchers together across disciplines, allowing exciting new connections and developments to be made.
A key collaboration is that between the University Hospital Southampton (UHS) and the University of Southampton (UoS) which has an ambitious five year strategy to strengthen links with industry and increase commercial research in line with NIHR and Government policy. This partnership with University Hospital Southampton NHS Foundation Trust, enables excellent clinical research through quality assured support, facilities and resources embedded at the heart of Southampton General Hospital and is ideally placed to engage in research drawing on a relatively stable regional population of over 3 million, for whom the UHS provides tertiary services across all specialities. Professor Iain Cameron, Dean of Medicine at the University of Southampton and Mark Hackett, CEO of University Hospital Southampton NHS Foundation Trust, head the partnership. Together with key research directors they drive development of Southampton’s clinical and biomedical research programmes and capacity.
Our different collaborations can be grouped into three key types:
We develop and maintain cross disciplinary collaborations with other Faculties within the University. Very strong links have been established and examples can be seen on our Research Group and Research Theme pages
The collaboration between the Institute of Developmental Sciences and the Somers Cancer Building. Together these buildings house the Centre for DOHaD, the Centre for Human Development, Stem Cells and Regeneration and the Cancer Research UK Centre.
We found new and maintain longstanding collaborations with external higher education institutions and other organisations both within the UK and worldwide. These collaborations are key to prosecuting the highest quality research globally.
We are are leading research into the role of epigenetic processes (DNA methylation, histone modifications and small interfering RNAs) in the induction and persistence of induced changes in the physiology of the offspring (Epigenetics). This work is closely aligned with studies supported by industry through the international research consortium EpiGen. This consortium is comprised of researchers from University of Southampton, Liggins Institute, University of Auckland, AgResearch New Zealand, the Medical Research Council and the Singapore Institute of Clinical Sciences
Our commercial collaborations are developing therapies and diagnostic technologies for patient benefit. Further information can be found on our Enterprise pages
Our membership of the MRC/ Association of British Pharmaceutica Industries (ABP) initiative in chronic obstructive pulmonary disorder (COPD) has strengthened our partnership with GlaxoSmithKline (GSK), Novartis, Astra Zeneca and Pfizer in the areas of clinical outcomes of microbiological colonisation in the lungs.
We are a founder member of the EU Innovative Medicines Initiative (IMI) public-private partnership for the discovery of biomarkers in asthma (UBIOPRED). Also, In 2010, we signed a broad collaborative research and development agreement (£3.5 million over 5 years) with GSK Biologicals to develop a programme of joint research focusing on characterizing mixed microbial communities and immunological
We are building partnerships with industry, creating independent companies, providing services such as consultancy or policy advice, and realising the financial benefits of our research through our collaborations with industry. To find out more visit our Enterprise webpages.